TNSN08270A1 - Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale - Google Patents

Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale

Info

Publication number
TNSN08270A1
TNSN08270A1 TNP2008000270A TNSN08270A TNSN08270A1 TN SN08270 A1 TNSN08270 A1 TN SN08270A1 TN P2008000270 A TNP2008000270 A TN P2008000270A TN SN08270 A TNSN08270 A TN SN08270A TN SN08270 A1 TNSN08270 A1 TN SN08270A1
Authority
TN
Tunisia
Prior art keywords
cell growth
abnormal cell
derivatives
pyrimidic
treating abnormal
Prior art date
Application number
TNP2008000270A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN08270A1 publication Critical patent/TNSN08270A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La présente invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de ce dernier, formule dans laquelle Ar est un groupe de formule (III), et R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, le sel dudit composé, R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p et q étant tels que définis. Ces nouveaux dérivés pyrimidiques sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez des mammifères. Cette invention concerne également un procédé d'utilisation de ces composés dans le traitement d'une croissance cellulaire anormale chez des mammifères, en particulier des êtres humains, ainsi que des compositions pharmaceutiques contenant lesdits composés.
TNP2008000270A 2005-12-21 2008-06-20 Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale TNSN08270A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21
PCT/IB2006/003655 WO2007072158A2 (fr) 2005-12-21 2006-12-11 Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale

Publications (1)

Publication Number Publication Date
TNSN08270A1 true TNSN08270A1 (fr) 2009-10-30

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000270A TNSN08270A1 (fr) 2005-12-21 2008-06-20 Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale

Country Status (30)

Country Link
US (1) US7820648B2 (fr)
EP (1) EP1966207A2 (fr)
JP (1) JP4332590B2 (fr)
KR (1) KR101060051B1 (fr)
CN (1) CN101346380B (fr)
AP (1) AP2008004488A0 (fr)
AR (1) AR058399A1 (fr)
AU (1) AU2006327871A1 (fr)
BR (1) BRPI0620324A2 (fr)
CA (1) CA2634646C (fr)
CR (1) CR10095A (fr)
DO (1) DOP2006000289A (fr)
EA (1) EA014551B1 (fr)
EC (1) ECSP088563A (fr)
GT (1) GT200600517A (fr)
HN (1) HN2006042221A (fr)
IL (1) IL191555A0 (fr)
MA (1) MA30075B1 (fr)
ME (1) MEP0908A (fr)
NL (1) NL2000375C2 (fr)
NO (1) NO20082338L (fr)
PE (1) PE20071138A1 (fr)
RS (1) RS20080272A (fr)
SV (1) SV2008002969A (fr)
TN (1) TNSN08270A1 (fr)
TW (1) TW200736258A (fr)
UA (1) UA89123C2 (fr)
UY (1) UY30051A1 (fr)
WO (1) WO2007072158A2 (fr)
ZA (1) ZA200804488B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP2041132A2 (fr) * 2006-07-06 2009-04-01 Boehringer Ingelheim International GmbH Nouveaux composés
TWI432427B (zh) 2006-10-23 2014-04-01 Cephalon Inc 作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
MX2009011090A (es) 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
KR20100049068A (ko) 2007-07-17 2010-05-11 리겔 파마슈티칼스, 인크. Ｐｋｃ 억제제로서의 시클릭 아민 치환된 피리미딘디아민
WO2009071535A1 (fr) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Nouveaux composés
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
EP2268621A1 (fr) * 2008-03-20 2011-01-05 Boehringer Ingelheim International GmbH Élaboration régiosélective de pyrimidines substituées
JP5551689B2 (ja) 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
EP2161259A1 (fr) 2008-09-03 2010-03-10 Bayer CropScience AG 4-haloalkyle-diaminopyrimidines substitués
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
CA2830129C (fr) 2011-03-24 2016-07-19 Chemilia Ab Nouveaux derives de pyrimidine
CN103987708B (zh) 2011-12-09 2016-06-22 奇斯药制品公司 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途
AU2012357038B2 (en) 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
JP6946412B2 (ja) 2016-07-18 2021-10-06 ヤンセン ファーマシューティカ エヌ．ベー． タウｐｅｔ画像化リガンド
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CA3204383A1 (fr) * 2021-01-07 2022-07-14 Rima AL-AWAR Composes thienyl et cycloalkyl aminopyrimidines utilises comme inhibiteurs de kinases nuak, compositions et utilisations de ceux-ci

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2514612A1 (fr) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta
WO2005111023A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement de la croissance cellulaire anormale
WO2005111016A1 (fr) * 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Also Published As

Publication number Publication date
IL191555A0 (en) 2008-12-29
GT200600517A (es) 2007-09-13
CN101346380A (zh) 2009-01-14
JP2009520807A (ja) 2009-05-28
US7820648B2 (en) 2010-10-26
ZA200804488B (en) 2009-05-27
UY30051A1 (es) 2007-07-31
NL2000375C2 (nl) 2008-01-03
WO2007072158A3 (fr) 2007-12-27
UA89123C2 (ru) 2009-12-25
EP1966207A2 (fr) 2008-09-10
ECSP088563A (es) 2008-07-30
CA2634646C (fr) 2012-04-10
EA200801287A1 (ru) 2008-10-30
PE20071138A1 (es) 2007-12-29
RS20080272A (en) 2009-07-15
MA30075B1 (fr) 2008-12-01
MEP0908A (xx) 2010-02-10
KR101060051B1 (ko) 2011-08-29
WO2007072158A2 (fr) 2007-06-28
WO2007072158A8 (fr) 2008-08-14
BRPI0620324A2 (pt) 2011-11-08
CA2634646A1 (fr) 2007-06-28
TW200736258A (en) 2007-10-01
CR10095A (es) 2008-07-17
US20080234303A1 (en) 2008-09-25
KR20080077026A (ko) 2008-08-20
JP4332590B2 (ja) 2009-09-16
EA014551B1 (ru) 2010-12-30
NL2000375A1 (nl) 2007-06-25
CN101346380B (zh) 2012-02-29
SV2008002969A (es) 2010-08-17
AU2006327871A1 (en) 2007-06-28
DOP2006000289A (es) 2007-07-31
HN2006042221A (es) 2010-01-18
NO20082338L (no) 2008-06-25
AP2008004488A0 (en) 2008-06-30
AR058399A1 (es) 2008-01-30

Similar Documents

Publication Publication Date Title
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
TN2009000544A1 (fr) Derives de benzimidazole
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA28747B1 (fr) Dérivés de pyridine
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA29926B1 (fr) Derives de pyrazine
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
TN2009000138A1 (fr) Biaryl-ether-urees
TN2009000450A1 (fr) Derives de pyridine
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA31894B1 (fr) Composes organiques
TNSN05051A1 (fr) Therapie combinee de maladies hyperproliferatives
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
WO2005037825A3 (fr) Inhibiteurs de la proteine kinase
MA24729A1 (fr) Macrolides nouveaux.
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4